Anavex Life Sciences Stock Price, News & Analysis (NASDAQ:AVXL)

$3.01 -0.39 (-11.47 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$3.40
Today's Range$3.00 - $3.45
52-Week Range$3.00 - $6.64
Volume914,060 shs
Average Volume296,800 shs
Market Capitalization$150.35 million
P/E Ratio-9.12
Dividend YieldN/A
Beta0.94

About Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences logoAnavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system (CNS) diseases. The Company's SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer's disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Debt-to-Equity RatioN/A
Current Ratio7.76%
Quick Ratio7.76%

Price-To-Earnings

Trailing P/E Ratio-9.12121212121212
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.58 per share
Price / Book5.19

Profitability

Trailing EPS($0.33)
Net Income$-13,460,000.00
Net MarginsN/A
Return on Equity-70.10%
Return on Assets-63.39%

Miscellaneous

Employees10
Outstanding Shares44,220,000

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Monday, December, 11th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.02. View Anavex Life Sciences' Earnings History.

When will Anavex Life Sciences make its next earnings announcement?

Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Anavex Life Sciences.

Where is Anavex Life Sciences' stock going? Where will Anavex Life Sciences' stock price be in 2018?

2 Wall Street analysts have issued 12-month price objectives for Anavex Life Sciences' shares. Their predictions range from $14.00 to $15.00. On average, they anticipate Anavex Life Sciences' stock price to reach $14.50 in the next twelve months. View Analyst Ratings for Anavex Life Sciences.

Who are some of Anavex Life Sciences' key competitors?

How do I buy Anavex Life Sciences stock?

Shares of Anavex Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of Anavex Life Sciences stock can currently be purchased for approximately $3.01.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $150.35 million. The biotechnology company earns $-13,460,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Anavex Life Sciences employs 10 workers across the globe.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]


MarketBeat Community Rating for Anavex Life Sciences (AVXL)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anavex Life Sciences (NASDAQ:AVXL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.50$14.50$15.00$13.67
Price Target Upside: 330.41% upside330.41% upside273.13% upside173.33% upside

Anavex Life Sciences (NASDAQ:AVXL) Consensus Price Target History

Price Target History for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
12/11/2017Maxim GroupSet Price TargetBuy$14.00HighView Rating Details
10/5/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Anavex Life Sciences (NASDAQ:AVXL) Earnings History and Estimates Chart

Earnings by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ AVXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018        
12/11/2017Q4 2017($0.10)($0.12)ViewListenView Earnings Details
8/7/2017Q3 2017($0.09)($0.09)ViewN/AView Earnings Details
5/10/2017Q2 2017($0.09)($0.09)ViewN/AView Earnings Details
2/7/2017Q1 2017($0.08)ViewN/AView Earnings Details
12/12/2016Q4 2016($0.08)($0.18)ViewN/AView Earnings Details
8/11/2016Q316($0.09)($0.06)ViewN/AView Earnings Details
5/11/2016Q2($0.16)($0.06)ViewN/AView Earnings Details
2/8/2016Q116($0.12)ViewN/AView Earnings Details
12/29/2015Q4 2015($0.54)ViewN/AView Earnings Details
8/17/2015Q3 2015($0.08)ViewN/AView Earnings Details
5/15/2015Q2 2015($0.12)ViewN/AView Earnings Details
2/18/2015Q1 2015($0.08)ViewN/AView Earnings Details
12/30/2014Q4 2014($0.96)ViewN/AView Earnings Details
8/13/2014Q3 2014($0.12)ViewN/AView Earnings Details
5/15/2014Q2 2014($0.12)ViewN/AView Earnings Details
2/14/2013Q1 2013($0.04)ViewN/AView Earnings Details
12/22/2011Q4 2011($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Anavex Life Sciences (NASDAQ:AVXL) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Anavex Life Sciences (NASDAQ:AVXL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anavex Life Sciences (NASDAQ AVXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 22.70%
Insider Trades by Quarter for Anavex Life Sciences (NASDAQ:AVXL)
Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ AVXL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2017Christopher U MisslingCEOBuy375$4.92$1,845.001,011,875View SEC Filing  
10/19/2017Christopher U MisslingInsiderBuy375$4.49$1,683.751,011,500View SEC Filing  
10/17/2017Christopher U MisslingInsiderBuy375$4.27$1,601.25View SEC Filing  
10/13/2017Christopher U MisslingInsiderBuy750$4.22$3,165.00View SEC Filing  
10/5/2017Christopher U MisslingInsiderBuy375$4.30$1,612.50View SEC Filing  
10/2/2017Christopher U MisslingInsiderBuy375$4.20$1,575.001,009,625View SEC Filing  
9/28/2017Christopher U MisslingInsiderBuy375$4.21$1,578.751,009,250View SEC Filing  
9/26/2017Christopher U MisslingInsiderBuy375$3.88$1,455.001,008,875View SEC Filing  
9/20/2017Christopher U MisslingInsiderBuy375$4.23$1,586.251,008,500View SEC Filing  
9/18/2017Christopher U MisslingInsiderBuy375$4.40$1,650.001,008,125View SEC Filing  
9/14/2017Christopher U MisslingInsiderBuy375$4.58$1,717.501,007,750View SEC Filing  
9/11/2017Christopher U MisslingInsiderBuy375$4.81$1,803.751,007,375View SEC Filing  
9/7/2017Christopher U MisslingInsiderBuy375$4.76$1,785.001,007,000View SEC Filing  
9/5/2017Christopher U MisslingInsiderBuy375$4.90$1,837.501,006,625View SEC Filing  
8/31/2017Christopher U MisslingInsiderBuy375$4.48$1,680.001,006,250View SEC Filing  
8/28/2017Christopher U MisslingInsiderBuy375$4.44$1,665.001,005,875View SEC Filing  
8/24/2017Christopher U MisslingInsiderBuy375$4.54$1,702.501,005,500View SEC Filing  
8/21/2017Christopher U MisslingInsiderBuy375$4.07$1,526.251,005,125View SEC Filing  
8/18/2017Christopher U MisslingInsiderBuy375$3.81$1,428.751,004,750View SEC Filing  
8/14/2017Christopher U MisslingInsiderBuy375$3.70$1,387.501,004,375View SEC Filing  
8/11/2017Christopher U MisslingInsiderBuy750$3.55$2,662.501,004,000View SEC Filing  
7/14/2015Christopher U MisslingCEOBuy1,000$0.52$520.00View SEC Filing  
7/13/2015Christopher U MisslingCEOBuy1,000$0.53$530.00View SEC Filing  
7/7/2015Christopher U MisslingCEOBuy2,000$0.49$980.00View SEC Filing  
7/1/2015Christopher U MisslingCEOBuy2,000$0.45$900.00View SEC Filing  
6/23/2015Christopher U MisslingCEOBuy1,000$0.47$470.00View SEC Filing  
6/22/2015Christopher U MisslingCEOBuy1,000$0.42$420.00View SEC Filing  
6/16/2015Christopher U MisslingCEOBuy1,000$0.44$440.00View SEC Filing  
6/15/2015Christopher U MisslingCEOBuy1,000$0.43$430.00View SEC Filing  
6/10/2015Christopher U MisslingCEOBuy1,000$0.36$360.00View SEC Filing  
6/8/2015Christopher U MisslingCEOBuy1,000$0.35$350.00View SEC Filing  
6/4/2015Christopher U MisslingCEOBuy1,000$0.37$370.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anavex Life Sciences (NASDAQ AVXL) News Headlines

Source:
DateHeadline
Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)
globenewswire.com - January 16 at 11:27 AM
Jazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head ComparisonJazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head Comparison
www.americanbankingnews.com - December 18 at 11:34 PM
Edited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMT
finance.yahoo.com - December 13 at 3:40 PM
Noble Financial Reaffirms Buy Rating for Anavex Life Sciences (AVXL)Noble Financial Reaffirms Buy Rating for Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 13 at 3:34 PM
Head-To-Head Comparison: Tetralogic Pharmaceuticals (TLOG) versus Anavex Life Sciences (AVXL)Head-To-Head Comparison: Tetralogic Pharmaceuticals (TLOG) versus Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 13 at 1:36 PM
Head to Head Analysis: Anavex Life Sciences (AVXL) and Osiris Therapeutics (OSIR)Head to Head Analysis: Anavex Life Sciences (AVXL) and Osiris Therapeutics (OSIR)
www.americanbankingnews.com - December 13 at 9:26 AM
Critical Analysis: Anavex Life Sciences (AVXL) & Tetralogic Pharmaceuticals (TLOG)Critical Analysis: Anavex Life Sciences (AVXL) & Tetralogic Pharmaceuticals (TLOG)
www.americanbankingnews.com - December 13 at 3:50 AM
42 Biggest Movers From Yesterday | Benzinga - Benzinga42 Biggest Movers From Yesterday | Benzinga - Benzinga
www.benzinga.com - December 12 at 12:03 PM
Anavex Life Sciences (AVXL) Releases  Earnings ResultsAnavex Life Sciences (AVXL) Releases Earnings Results
www.americanbankingnews.com - December 12 at 9:26 AM
Anavex Life Sciences (AVXL) vs. Grifols SA, Barcelona (GRFS) Head to Head AnalysisAnavex Life Sciences (AVXL) vs. Grifols SA, Barcelona (GRFS) Head to Head Analysis
www.americanbankingnews.com - December 11 at 6:26 PM
Anavex Life Sciences (AVXL) PT Set at $14.00 by Maxim GroupAnavex Life Sciences (AVXL) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - December 11 at 5:08 PM
Zacks: Anavex Life Sciences Corp. (AVXL) Given Average Rating of "Strong Buy" by AnalystsZacks: Anavex Life Sciences Corp. (AVXL) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 5 at 11:30 AM
Critical Review: Windtree Therapeutics (WINT) vs. Anavex Life Sciences (AVXL)Critical Review: Windtree Therapeutics (WINT) vs. Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 5 at 5:28 AM
Critical Analysis: Anavex Life Sciences (AVXL) vs. Mirati Therapeutics (MRTX)Critical Analysis: Anavex Life Sciences (AVXL) vs. Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 4 at 8:44 AM
Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on MondayAnavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - December 4 at 1:38 AM
Anavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per ShareAnavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 2 at 1:38 PM
Windtree Therapeutics (WINT) & Anavex Life Sciences (AVXL) Head to Head AnalysisWindtree Therapeutics (WINT) & Anavex Life Sciences (AVXL) Head to Head Analysis
www.americanbankingnews.com - November 30 at 3:12 AM
Reviewing Osiris Therapeutics (OSIR) & Anavex Life Sciences Corp. (AVXL)Reviewing Osiris Therapeutics (OSIR) & Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - November 22 at 11:31 AM
Anavex Life Sciences Corp. (AVXL) Cut to "Sell" at ValuEngineAnavex Life Sciences Corp. (AVXL) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - November 22 at 12:56 AM
Anavex Life Sciences (AVXL) Says Newly Published Data on AD Research Demonstrate Neuroprotective Features of ... - StreetInsider.comAnavex Life Sciences (AVXL) Says Newly Published Data on AD Research Demonstrate Neuroprotective Features of ... - StreetInsider.com
www.streetinsider.com - November 21 at 4:48 PM
Windtree Therapeutics (WINT) vs. Anavex Life Sciences Corp. (AVXL) Head-To-Head SurveyWindtree Therapeutics (WINT) vs. Anavex Life Sciences Corp. (AVXL) Head-To-Head Survey
www.americanbankingnews.com - November 14 at 9:22 PM
 Anavex Life Sciences Corp. (AVXL) Given Consensus Recommendation of "Strong Buy" by Brokerages Anavex Life Sciences Corp. (AVXL) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 14 at 1:30 AM
Alzheimers Disease: Anavex 2-73 And The Long Road Home ... - Seeking AlphaAlzheimer's Disease: Anavex 2-73 And The Long Road Home ... - Seeking Alpha
seekingalpha.com - November 8 at 11:41 PM
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in ... - GlobeNewswire (press release)Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in ... - GlobeNewswire (press release)
globenewswire.com - November 8 at 6:40 PM
FDA Ruling On DVAX This Week, XNCR On Watch, Its Impressive But Early For AVXLFDA Ruling On DVAX This Week, XNCR On Watch, It's Impressive But Early For AVXL
www.rttnews.com - November 5 at 9:11 PM
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimers Disease Treatment ANAVEX®2-73 at ... - GlobeNewswire (press release)Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer's Disease Treatment ANAVEX®2-73 at ... - GlobeNewswire (press release)
globenewswire.com - November 4 at 10:49 PM
Anavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target by Maxim Group AnalystsAnavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - October 30 at 6:34 PM
Anavex Life Sciences (AVXL) Presents Additional Data on ANAVEX2-73 at Conference - StreetInsider.comAnavex Life Sciences (AVXL) Presents Additional Data on ANAVEX2-73 at Conference - StreetInsider.com
www.streetinsider.com - October 30 at 5:17 PM
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinsons Disease Therapeutics ConferenceAnavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference
finance.yahoo.com - October 30 at 5:17 PM
Anavex Life Sciences (AVXL) Announces New Data Related to MS Presented at ECTRIMS-ACTRIMS Meeting - StreetInsider.comAnavex Life Sciences (AVXL) Announces New Data Related to MS Presented at ECTRIMS-ACTRIMS Meeting - StreetInsider.com
www.streetinsider.com - October 27 at 11:28 PM
First Week Of December 15th Options Trading For Anavex Life Sciences (AVXL)First Week Of December 15th Options Trading For Anavex Life Sciences (AVXL)
www.thestreet.com - October 27 at 6:24 PM
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
finance.yahoo.com - October 27 at 6:24 PM
 Analysts Expect Anavex Life Sciences Corp. (AVXL) Will Announce Earnings of -$0.10 Per Share Analysts Expect Anavex Life Sciences Corp. (AVXL) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - October 24 at 12:20 PM
Anavex Life Sciences (AVXL) Presents Analysis of ANAVEX 2-73 Phase 2a Data - SlideshowAnavex Life Sciences (AVXL) Presents Analysis of ANAVEX 2-73 Phase 2a Data - Slideshow
seekingalpha.com - October 13 at 4:53 PM
Anavex Life Sciences (AVXL) Presents Analysis of ANAVEX 2-73 Phase 2a Data - SlideshowAnavex Life Sciences (AVXL) Presents Analysis of ANAVEX 2-73 Phase 2a Data - Slideshow
seekingalpha.com - October 13 at 4:53 PM
Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit ... - NasdaqMid-Morning Market Update: Markets Edge Lower; JPMorgan Profit ... - Nasdaq
www.nasdaq.com - October 13 at 3:07 AM
Anavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target at Maxim GroupAnavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target at Maxim Group
www.americanbankingnews.com - October 13 at 12:32 AM
Anavexs Alzheimers candidate ANAVEX2-73 shows encouraging pharmacodynamics in mid-stage study; shares ahead 8% premarketAnavex's Alzheimer's candidate ANAVEX2-73 shows encouraging pharmacodynamics in mid-stage study; shares ahead 8% premarket
seekingalpha.com - October 12 at 10:06 PM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-ModerateAnavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate
www.nasdaq.com - October 12 at 10:06 PM
30 Stocks Moving In Thursdays Pre-Market Session - Benzinga30 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - October 12 at 5:03 PM
Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates - BenzingaMid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates - Benzinga
www.benzinga.com - October 12 at 5:03 PM
33 Stocks Moving In Thursdays Mid-Day Session - Benzinga33 Stocks Moving In Thursday's Mid-Day Session - Benzinga
www.benzinga.com - October 12 at 5:03 PM
Anavex Life Sciences (AVXL) Reports PK and PD Data from Phase 2a Trial of ANAVEX 2-73 in Mild-to-Moderate AD - StreetInsider.comAnavex Life Sciences (AVXL) Reports PK and PD Data from Phase 2a Trial of ANAVEX 2-73 in Mild-to-Moderate AD - StreetInsider.com
www.streetinsider.com - October 12 at 5:03 PM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ETAnavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET
finance.yahoo.com - October 12 at 5:03 PM
Anavex Life Sciences Stock Sees Short Interest Decrease By 20%Anavex Life Sciences Stock Sees Short Interest Decrease By 20%
www.thestreet.com - October 11 at 5:44 PM
Anavex Life Sciences Corp.s (AVXL) Buy Rating Reaffirmed at Noble FinancialAnavex Life Sciences Corp.'s (AVXL) Buy Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - September 29 at 6:38 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 23 at 1:13 AM
Anavex Life Sciences Corp. (AVXL) vs. Its Peers Head-To-Head SurveyAnavex Life Sciences Corp. (AVXL) vs. Its Peers Head-To-Head Survey
www.americanbankingnews.com - September 18 at 10:30 PM
Anavex Life Sciences Corp. (AVXL) vs. Its Competitors Head to Head SurveyAnavex Life Sciences Corp. (AVXL) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - September 14 at 8:20 AM
Contrasting Anavex Life Sciences Corp. (AVXL) and its PeersContrasting Anavex Life Sciences Corp. (AVXL) and its Peers
www.americanbankingnews.com - September 9 at 10:26 AM

SEC Filings

Anavex Life Sciences (NASDAQ:AVXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anavex Life Sciences (NASDAQ:AVXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anavex Life Sciences (NASDAQ AVXL) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.